Daniel Carlson

2126 POSTS 694 COMMENTS
Front Page

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at...

Daniel Carlson -
0
Front Page

Wrapping Up May

Daniel Carlson -
8
Front Page

Keep The Faith…Rubber Eventually Meets Road

Daniel Carlson -
9
Front Page

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present...

Daniel Carlson -
0
Front Page

May 22, 2023…Premium Subscriber Update

Daniel Carlson -
3
Anixa

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer...

Daniel Carlson -
3
Front Page

Back in the Saddle

Daniel Carlson -
3
Front Page

IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

Daniel Carlson -
0
Front Page

Spectra7 Announces 50% Y-o-Y Revenue Growth in First Quarter 2023, Affirms...

Daniel Carlson -
0
Newsletters

Upcoming Catalysts For A Catalyst Driven Market

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental...

Daniel Carlson -
5
Front Page

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented...

Daniel Carlson -
0
Front Page

May 2, 2023…Trading Update

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized...

Daniel Carlson -
0
Front Page

This Time It’s Different!

Daniel Carlson -
10
Front Page

April 27th, 2023 Trade Update…ATOM and INAB

Daniel Carlson -
1
Atomera

Atomera Signs Commercial License Agreement with STMicroelectronics

Daniel Carlson -
1
Front Page

April 26, 2023 Trade Update

Daniel Carlson -
5
Front Page

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in...

Daniel Carlson -
0
Front Page

Spectra7 Announces 107% Revenue Growth for 2022, Pre-announces Q1 2023 and...

Daniel Carlson -
0
Front Page

IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and...

Daniel Carlson -
0
Front Page

Anixa Delivers On The Data While The Stock Rollercoasters

Daniel Carlson -
3
Front Page

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

Daniel Carlson -
0
Anixa

Recapping Anixa…Premium Subscriber Update

Daniel Carlson -
5
Anixa

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1...

Daniel Carlson -
0
Anixa

Anixa’s Breast Cancer Vaccine Looks Spot On…An Interview With Dr. Amit...

Daniel Carlson -
1
Front Page

IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches...

Daniel Carlson -
0
Front Page

Coming Out Of Hibernation?

Daniel Carlson -
7
Front Page

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent...

Daniel Carlson -
0
Front Page

IN8bio to Present New Positive Clinical Data from Phase 1 Trial...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR...

Daniel Carlson -
0
Front Page

How Low Can It Go?

Daniel Carlson -
1
Front Page

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application...

Daniel Carlson -
0
Front Page

Three Months Down

Daniel Carlson -
5
Front Page

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study,...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson -
0
Front Page

3 Dot Lounge…

Daniel Carlson -
5
Front Page

Movano Health Provides Business Update and Reports Fourth Quarter 2022 Financial...

Daniel Carlson -
0
Front Page

Upcoming Catalysts (or, Meaningful Events That Probably Won’t Help Your Portfolio)

Daniel Carlson -
2
Front Page

March 17, 2023 Trade Update

Daniel Carlson -
0
Front Page

IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform...

Daniel Carlson -
0
Front Page

Movano Health Awarded Three New Core Patents Validating its Cutting-Edge Approach...

Daniel Carlson -
0
Front Page

Premium Subscriber Update SPVNF, March 14th

Daniel Carlson -
4
Front Page

Spectra7 Announces 112G PAM4 Design-In with Zhaolong for North American and...

Daniel Carlson -
0
Front Page

Black Swan Diving

Daniel Carlson -
12
Front Page

Spectra7 Microsystems Inc. Announces Private Placement of $5.89 Million CAD

Daniel Carlson -
0
Front Page

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the...

Daniel Carlson -
0
Front Page

What Women Want: Accuracy is Critical to Future Wearable Use

Daniel Carlson -
4
Front Page

INmune Bio: Things Turning For The Better

Daniel Carlson -
7
Front Page

Premium Subscriber Update INMB, TFFP, SPVNF & BWLKF

Daniel Carlson -
6
Front Page

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing...

Daniel Carlson -
0
Front Page

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on...

Daniel Carlson -
0
Front Page

Market Tests Support…Here’s What To Do.

Daniel Carlson -
4
Front Page

Trade Alert for Premium Subscribers, Feb. 23 2023

Daniel Carlson -
4
Front Page

IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board

Daniel Carlson -
0
Front Page

Trading Update for Premium Subscribers, Feb. 18, 2023

Daniel Carlson -
4
Front Page

Execution is Key

Daniel Carlson -
15
Front Page

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform,...

Daniel Carlson -
0
Front Page

Spectra7 Announces New 800Gbps Design Win with ACES for North American...

Daniel Carlson -
0
Front Page

Ruminating On INmune, Anixa and More

Daniel Carlson -
18
Front Page

Spectra7 Targets High Growth 800Gbps AI Server Market

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development...

Daniel Carlson -
0
Front Page

Trading Update, February 8th 2023

Daniel Carlson -
1
Front Page

Double Trouble

Daniel Carlson -
9
Front Page

Spectra7 to Showcase 200 and 400Gbps Connectivity using Active Copper Cables...

Daniel Carlson -
0
Front Page

Awaiting Liftoff…Catalyst List

Daniel Carlson -
6
Front Page

Trading Update, January 27th 2023

Daniel Carlson -
0
Front Page

Movano Health Prices $6.5 Million Public Offering

Daniel Carlson -
0
Front Page

INmune in DMD…Yet Another Indication of Future Success

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach...

Daniel Carlson -
0
Front Page

Looking for 3-5X This Year? These Two Jackpot Stocks Offer That...

Daniel Carlson -
2
Front Page

Spectra7 Announces Preliminary Fourth Quarter and Annual Financial Results for the...

Daniel Carlson -
0
enVVeno

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and...

Daniel Carlson -
0
Front Page

Notes for Premium Subscribers

Daniel Carlson -
9
Front Page

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path...

Daniel Carlson -
0
Front Page

The January Halftime Report

Daniel Carlson -
4
Front Page

The 2023 Game Plan

Daniel Carlson -
1
Front Page

Spectra7, ACON, and Mo-Link to Demonstrate Thunderbolt 4 Active Copper Cables...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief...

Daniel Carlson -
6
Front Page

For The TW Portfolio, Our FATE Awaits

Daniel Carlson -
6
Uncategorized

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284...

Daniel Carlson -
0
Front Page

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

Daniel Carlson -
2
Front Page

IN8bio to Present at Biotech Showcase 2023 in San Francisco

Daniel Carlson -
0
Front Page

The Light at the End of the Tunnel

Daniel Carlson -
9
Front Page

Trading Thoughts As We Prepare To Swap Out The Calendar

Daniel Carlson -
0
Front Page

Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely...

Daniel Carlson -
2
Front Page

Trading Alert: Initiating a New Position

Daniel Carlson -
3
Front Page

Holiday Cheers!

Daniel Carlson -
0
Front Page

Movano Health On Track to File First FDA Submission for its...

Daniel Carlson -
0
Front Page

Movano Health Announces Launch of Smart Ring Beta Program with Novant...

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative...

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284...

Daniel Carlson -
0
Front Page

Santa Claus Ain’t Coming To Town

Daniel Carlson -
11
Anixa

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell...

Daniel Carlson -
2
Front Page

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Leadership Transition

Daniel Carlson -
5
Front Page

Informed Decisions

Daniel Carlson -
8
Front Page

Spectra7 Announces Third Quarter 2022 Financial Results

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance...

Daniel Carlson -
0
Front Page

Pardon Me

Daniel Carlson -
2
Front Page

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug...

Daniel Carlson -
0
Front Page

Pot Watching…

Daniel Carlson -
14
Front Page

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

Daniel Carlson -
10
Front Page

Trading Blog, November 17, 2022

Daniel Carlson -
5
Front Page

Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium...

Daniel Carlson -
0
Front Page

Trading Blog, November 16, 2022

Daniel Carlson -
3
Front Page

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence...

Daniel Carlson -
0
Front Page

Crashing Bitcoins and Other Thoughts

Daniel Carlson -
18
Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson -
0
Front Page

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve...

Daniel Carlson -
0
Front Page

Dinner Table Talk

Daniel Carlson -
12
Front Page

ParkerVision Secures Patent License Agreement with Hisense

Daniel Carlson -
3
Front Page

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop...

Daniel Carlson -
6
Front Page

TFF Delays Data and Other Thoughts Heading Into Year-End 2022

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus...

Daniel Carlson -
12
Front Page

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder...

Daniel Carlson -
5
Front Page

Sanford M. Litvack Joins ParkerVision Board of Directors

Daniel Carlson -
0
Anixa

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer...

Daniel Carlson -
0
Front Page

Counting Down to Catalysts

Daniel Carlson -
13
Front Page

Spectra7 Announces Return of Chief Executive Officer Raouf Halim to Half...

Daniel Carlson -
1
Front Page

enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate...

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast...

Daniel Carlson -
0
Front Page

Keeping An Eye On The Trees

Daniel Carlson -
5
Front Page

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple...

Daniel Carlson -
0
Front Page

Resetting Expectations

Daniel Carlson -
7
Front Page

Spectra7 Announces Preliminary Third Quarter 2022 Revenue and Second Half 2022...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film...

Daniel Carlson -
4
Anixa

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at...

Daniel Carlson -
0
Front Page

Bringing Down the House

Daniel Carlson -
21
Front Page

Welcome Back???

Daniel Carlson -
7
Front Page

enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous...

Daniel Carlson -
0
Front Page

Trading Alert, Sept. 15th, 2022

Daniel Carlson -
0
Front Page

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of...

Daniel Carlson -
0
Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Presented at the...

Daniel Carlson -
0
Front Page

Moving Day

Daniel Carlson -
15
Front Page

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder...

Daniel Carlson -
1
Front Page

Don’t Fight The FED. TW’s August Recap.

Daniel Carlson -
0
Front Page

The Bear Returns

Daniel Carlson -
9
Uncategorized

Spectra7 Announces Closing of the Upsized Convertible Debenture Financing of $8.9...

Daniel Carlson -
0
Front Page

Spectra7 Announces Upsizing of Convertible Debenture Financing to $9.0 Million

Daniel Carlson -
0
Front Page

When News Is Good

Daniel Carlson -
0
Front Page

Trading Alert, August 18th, 2022

Daniel Carlson -
0
Front Page

enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

Daniel Carlson -
0
Anixa

CAR-T Trial Launches…An Interview With Dr. Amit Kumar, CEO of Anixa

Daniel Carlson -
1
Anixa

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer...

Daniel Carlson -
0
Front Page

Pendulum Swings

Daniel Carlson -
5
Front Page

Movano Expands Go-To-Market Team with Vice President of UX and UI...

Daniel Carlson -
0
Front Page

Movano Ring Exceeds Accuracy Targets for SpO2 and Heart Rate Monitoring...

Daniel Carlson -
0
Front Page

The Domino Effect

Daniel Carlson -
11
Front Page

Trading Alert, August 5th, 2022

Daniel Carlson -
0
Front Page

Trading Alert, August 2nd, 2022

Daniel Carlson -
0
Front Page

Micros Rallied in July, Can It Continue?

Daniel Carlson -
3
Front Page

Spectra7 Announces $8.0 Million Convertible Debenture Financing; Closing of First Tranche

Daniel Carlson -
0
Fortress Bio

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral...

Daniel Carlson -
0
Uncategorized

INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in...

Daniel Carlson -
0
Front Page

Dog Days of Summer

Daniel Carlson -
1
Anixa

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast...

Daniel Carlson -
2
Front Page

Trading Alert, July 19th, 2022

Daniel Carlson -
2
Front Page

Taking the Long View on TFF

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

Daniel Carlson -
3
Front Page

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical...

Daniel Carlson -
0
Front Page

Catalysts Aplenty, a 2nd Half Preview

Daniel Carlson -
1
Front Page

Texas Court Grants ParkerVision Motion to Add Willfulness to Intel Complaint

Daniel Carlson -
2
Front Page

enVVeno Medical Announces the Issuance of a New Unique Category III...

Daniel Carlson -
0
Amryt

Amryt Presents New Analyses from the EASE Phase 3 Trial in...

Daniel Carlson -
0
Front Page

June in Review

Daniel Carlson -
3
Front Page

This Week’s Newsletter

Daniel Carlson -
0
Amryt

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional...

Daniel Carlson -
0
Front Page

Spectra7 Expands Availability of Active Copper Cables with new Design-in with...

Daniel Carlson -
0
Front Page

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS...

Daniel Carlson -
2
Anixa

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and...

Daniel Carlson -
0
Anixa

Going Downhill

Daniel Carlson -
2
Front Page

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on...

Daniel Carlson -
0
Amryt

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED...

Daniel Carlson -
0
Anixa

High Degree of Confidence

Daniel Carlson -
7
Amryt

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials...

Daniel Carlson -
0
Atomera

June Gloom

Daniel Carlson -
0
Fortress Bio

Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial...

Daniel Carlson -
0
Front Page

Spectra7 Announces First Quarter 2022 Financial Results

Daniel Carlson -
0
Front Page

Establishing Lows

Daniel Carlson -
2
Front Page

INMB: Making Sense of The FDA Clinical Hold

Daniel Carlson -
5
Front Page

INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as...

Daniel Carlson -
1
Anixa

CEO Knows Best

Daniel Carlson -
2
Fortress Bio

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency...

Daniel Carlson -
0
Front Page

Quest Resource Holding Corporation Reports First Quarter 2022 Financial Results

Daniel Carlson -
0
Front Page

INmune Bio Looks to Change The CNS Landscape

Daniel Carlson -
1
Front Page

It’s Still The Early Innings

Daniel Carlson -
11
Front Page

Movano Successfully Completes Functional Testing of Smallest Ever Custom mmWave Sensor...

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business...

Daniel Carlson -
4
Front Page

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray...

Daniel Carlson -
1
Anixa

Stepping on Rakes

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business...

Daniel Carlson -
0
Front Page

Top Global Virtual Reality Gaming Company Chooses Spectra7 Chipset to Power...

Daniel Carlson -
0
Front Page

enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin...

Daniel Carlson -
0
Front Page

Spectra7 Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Daniel Carlson -
0
Anixa

The Rolling Correction Gathers Steam…

Daniel Carlson -
3
Anixa

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the...

Daniel Carlson -
2
Atomera

Atomera Provides First Quarter 2022 Results

Daniel Carlson -
0
Atomera

Atomera Enters into Joint Development Agreement with Major Foundry

Daniel Carlson -
0
Front Page

Does Nkarta’s Positive NK Data Have Any Relation To INmune Bio’s...

Daniel Carlson -
0
Fortress Bio

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted...

Daniel Carlson -
2
Amryt

It’s A Process

Daniel Carlson -
7
Amryt

CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic...

Daniel Carlson -
0
Front Page

TFF Announces Data from Phase 1 Study of Niclosamide

Daniel Carlson -
3
Front Page

Movano Hires Chief Marketing Officer to Implement Its Multi-Channel Marketing Strategy...

Daniel Carlson -
0
Company

How’s Your Balance (Sheet)?

Daniel Carlson -
8
Atomera

Atomera Successfully Meets Requirements of Joint Development Agreement

Daniel Carlson -
1
Front Page

INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial...

Daniel Carlson -
0
Amryt

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. to Present Preclinical Data on INB03 at the...

Daniel Carlson -
0
Front Page

Your Home Is Worth What???

Daniel Carlson -
5
Anixa

Anixa Zoom Recap

Daniel Carlson -
1
Front Page

Spectra7 Announces Preliminary First Quarter 2022 Revenue and Provides Business Update

Daniel Carlson -
0
Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at The...

Daniel Carlson -
0
Front Page

All Coming Together

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in...

Daniel Carlson -
0
Front Page

The New Reality

Daniel Carlson -
2
Anixa

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase...

Daniel Carlson -
6
Front Page

Spectra7 Partners with Volex to Deliver Next Generation 800Gbps Data Center...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host...

Daniel Carlson -
0
Front Page

enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and...

Daniel Carlson -
0
Front Page

Separating the Wheat From the Chaff

Daniel Carlson -
8
Front Page

INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022

Daniel Carlson -
0
Front Page

Movano Inc. Provides Business Update and Reports Fourth Quarter 2021 Financial...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results...

Daniel Carlson -
2
Front Page

Update on INmune, TFF Pharma and DarioHealth

Daniel Carlson -
5
Fortress Bio

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate,...

Daniel Carlson -
0
Front Page

Buy The Rumor, Sell The News

Daniel Carlson -
3
Front Page

For Those Looking To Play A Bounce, Here’s A Candidate

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The...

Daniel Carlson -
3
Front Page

INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 –...

Daniel Carlson -
0
Anixa

Groundhog Day

Daniel Carlson -
12
Front Page

Orlando Court Grants Qualcomm Motion Blocking ParkerVision’s Presentation of Key Evidence...

Daniel Carlson -
2
Front Page

QUEST RESOURCE HOLDING CORPORATION ANNOUNCES STRONG PRELIMINARY FOURTH QUARTER 2021 FINANCIAL...

Daniel Carlson -
0
Anixa

ANIX Update

Daniel Carlson -
1
Front Page

One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery

Daniel Carlson -
0
Amryt

Amryt Announces 22% growth in FY 2021 Revenues to $222.5M

Daniel Carlson -
0
Amryt

Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules)

Daniel Carlson -
0
Front Page

This Trend is NOT Your Friend

Daniel Carlson -
8
Front Page

INmune, a very brief update

Daniel Carlson -
3
Atomera

Atomera’s Enhanced MSTcad Helps Chip Companies Quickly Realize MST Benefits

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and...

Daniel Carlson -
3
Front Page

TFFP: More Thoughts Regarding NICLOSAMIDE

Daniel Carlson -
3
Amryt

Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA

Daniel Carlson -
0
Amryt

Putin It In Perspective

Daniel Carlson -
7
Front Page

Positive Long-Term VenoValve® First-in-Human Data Presented at 34th Annual Meeting of...

Daniel Carlson -
5
Front Page

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the...

Daniel Carlson -
5
Front Page

Good News

Daniel Carlson -
1
Front Page

enVVeno Medical Announces ISO 13485 Certification

Daniel Carlson -
0
Front Page

Updating My Thinking On INmune (INMB) and TFF Pharma (TFFP)

Daniel Carlson -
6
Front Page

Movano Completes its Second Glucose Pilot Study

Daniel Carlson -
0
Front Page

Movano Announces Two Key Hires to Further Its Go-To-Market Strategy for...

Daniel Carlson -
0
Atomera

End Game

Daniel Carlson -
2
Atomera

Quest and Atomera Spike…Should You Be A Buyer?

Daniel Carlson -
0
Atomera

Atomera Licenses MST® Technology to Semiconductor Foundry

Daniel Carlson -
0
Front Page

Updates From Several Management Calls

Daniel Carlson -
4
Atomera

Metamorphosis

Daniel Carlson -
2
Front Page

This Week’s Billboard Headline…Glenn Mattes Stars As Rocky Balboa!

Daniel Carlson -
6
Amryt

Amryt Announces Oleogel-S10 EMA Regulatory Update

Daniel Carlson -
0
Front Page

Spectra7: Hyper-Growth in Hyper-Scale Data Centers

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong...

Daniel Carlson -
0
Fortress Bio

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of...

Daniel Carlson -
0
Front Page

PTAB Issues Rulings in ParkerVision IPRs Filed by Intel

Daniel Carlson -
0
Front Page

Spectra7 Announces Preliminary Fourth Quarter 2021 Revenue and Record Order Backlog...

Daniel Carlson -
0
Front Page

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for...

Daniel Carlson -
0
Anixa

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease...

Daniel Carlson -
0
Front Page

Welcome To The Terrordome

Daniel Carlson -
3
Front Page

An INKmune Update, Catalysts Included…

Daniel Carlson -
0
Anixa

ParkerVision’s Time is Nigh…

Daniel Carlson -
4
Front Page

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute...

Daniel Carlson -
0
Fortress Bio

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule...

Daniel Carlson -
0
Amryt

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role...

Daniel Carlson -
0
Anixa

Welcome to 2022?

Daniel Carlson -
6
Front Page

Movano Completes Blood Pressure Study with 110 Participants

Daniel Carlson -
0
Amryt

Happy New Year!!!

Daniel Carlson -
8
Front Page

Movano Unveils Smart Ring Designed for Women Seeking More Approachable Health...

Daniel Carlson -
3
Front Page

Trading Blog, December 22, 2021

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled...

Daniel Carlson -
1
Front Page

Who Believes? Santa Rally Coming…

Daniel Carlson -
14
Front Page

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in...

Daniel Carlson -
0
Front Page

No QUESTion, This Stock’s A Winner

Daniel Carlson -
4
Front Page

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to...

Daniel Carlson -
0
Front Page

Quest Resource Holding Acquires Two Asset-Light Waste Services Companies

Daniel Carlson -
0
Anixa

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected...

Daniel Carlson -
0
Fortress Bio

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

Daniel Carlson -
0
Anixa

Bottom Picking

Daniel Carlson -
3
Front Page

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society...

Daniel Carlson -
0
Atomera

Atomera Breathes New Life into Moore’s Law for Power and Analog...

Daniel Carlson -
0
Front Page

Is OMICRON Potentially Positive For TFF Pharma?

Daniel Carlson -
8
Fortress Bio

Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol...

Daniel Carlson -
0
Anixa

Turkey Shoot…December Preview

Daniel Carlson -
2
Front Page

Trading Blog, November 23rd, 2021

Daniel Carlson -
0
Amryt

Amryt Provides Update on Regulatory Review Process for Oleogel-S10

Daniel Carlson -
0
Amryt

Amryt Pharma plc Announces the Cancellation of Admission of its Ordinary...

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Share Repurchase Program

Daniel Carlson -
0
Front Page

The Worst Bull Market Ever

Daniel Carlson -
6
Front Page

Trading Blog, November 18th, 2021

Daniel Carlson -
0
Atomera

Atomera Reaches 300 Patents Focused on Perfecting Atomic Level Engineering and...

Daniel Carlson -
0
Front Page

Quest Resource Holding Corp. Reports 3rd Quarter 2021 Financial Results

Daniel Carlson -
0
Fortress Bio

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business...

Daniel Carlson -
0
Front Page

Three Non-Biotech Stocks

Daniel Carlson -
4
Fortress Bio

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted...

Daniel Carlson -
0
Front Page

enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate...

Daniel Carlson -
5
Front Page

QUEST RESOURCE HOLDING CORPORATION ACQUIRES ASSET-LIGHT WASTE SERVICES PROVIDER

Daniel Carlson -
0
Front Page

Notes from INKmune Update

Daniel Carlson -
3
Front Page

Trading Blog, November 9th, 2021

Daniel Carlson -
6
Front Page

LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a...

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for...

Daniel Carlson -
1
Anixa

Asymmetric Risk

Daniel Carlson -
5
Front Page

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business...

Daniel Carlson -
4
Amryt

Amryt Reports Strong Q3 2021 Results

Daniel Carlson -
0
Front Page

ParkerVision Receives Favorable Markman Recommendations in ParkerVision v. Hisense and TCL

Daniel Carlson -
0
Front Page

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights

Daniel Carlson -
0
Front Page

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®,...

Daniel Carlson -
0
Atomera

Trick or Treat? October Review

Daniel Carlson -
4
Front Page

LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement

Daniel Carlson -
0
Atomera

Atomera Provides Third Quarter 2021 Results

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical...

Daniel Carlson -
0
Front Page

Code Ocean Selected by Lantern Pharma to Power A.I. and Computational...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the...

Daniel Carlson -
0
Front Page

Trading Blog, October 26th, 2021

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in...

Daniel Carlson -
0
Front Page

LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing

Daniel Carlson -
0
Anixa

Training My Thoughts

Daniel Carlson -
0
Front Page

enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S....

Daniel Carlson -
0
Amryt

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

Daniel Carlson -
0
Anixa

Saturday Morning Musings

Daniel Carlson -
6
Front Page

Why TFF’s Hamster Data Is Bigger Than Investors Think

Daniel Carlson -
2
Front Page

Trading Blog, October 14th, 2021

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing...

Daniel Carlson -
0
Front Page

Ondas Holdings Inc. Announces Strategic Partnership with Dynam.AI

Daniel Carlson -
0
Anixa

$8 Paddle Balls?

Daniel Carlson -
2
Fortress Bio

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101,...

Daniel Carlson -
0
Front Page

LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy...

Daniel Carlson -
2
Front Page

Trading Blog, October 5th, 2021

Daniel Carlson -
3
Amryt

October Awaits

Daniel Carlson -
2
Anixa

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its...

Daniel Carlson -
0
Front Page

LexaGene Reports on Recent Veterinary Trade Shows

Daniel Carlson -
0
Fortress Bio

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca...

Daniel Carlson -
0
Front Page

Trading Blog, Sept. 28th, 2021

Daniel Carlson -
0
Front Page

Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership...

Daniel Carlson -
0
Front Page

Cash is King

Daniel Carlson -
1
Front Page

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial...

Daniel Carlson -
1
Front Page

Trading Blog, Sept. 22nd, 2021

Daniel Carlson -
1
Front Page

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development...

Daniel Carlson -
0
Front Page

Ondas Networks to Present at Annual Railway System Supplier Show

Daniel Carlson -
0
Amryt

When The Tide Goes Out, You See Who’s Swimming Naked…

Daniel Carlson -
6
Front Page

Trading Blog, Sept. 16th, 2021

Daniel Carlson -
6
Front Page

Siemens Mobility to present Airlink Wireless Radio System in Live DemoCast

Daniel Carlson -
0
Anixa

Anixa Biosciences’ Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming...

Daniel Carlson -
0
Amryt

Amryt Raises Full Year 2021 Revenue Guidance to $220M – $225M

Daniel Carlson -
0
Front Page

Rolling Over? Markets Look Toppy To Me…

Daniel Carlson -
1
Front Page

Trade Alert, Sept. 8, 2021

Daniel Carlson -
6
Front Page

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market...

Daniel Carlson -
0
Anixa

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

Daniel Carlson -
0
Front Page

LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial...

Daniel Carlson -
1
Front Page

ParkerVision Secures Patent License and Settlement Agreement with Zyxel

Daniel Carlson -
0
Anixa

A September To Remember?

Daniel Carlson -
1
Front Page

LexaGene’s MiQLab(TM) System Featured at Three Key Veterinary Tradeshows

Daniel Carlson -
0
Front Page

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry...

Daniel Carlson -
0
Front Page

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF...

Daniel Carlson -
0
Front Page

FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate...

Daniel Carlson -
0
Anixa

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate...

Daniel Carlson -
0
Front Page

Small Caps Rebound…August Recap

Daniel Carlson -
5
Front Page

INKmune Induces Memory-Like NK Cells…This Is A Very Big Deal

Daniel Carlson -
6
Anixa

Anixa Biosciences’ Covid-19 Compounds Expected to be Effective Against the Delta...

Daniel Carlson -
0
Amryt

Old Fashioned Sunday

Daniel Carlson -
5
Front Page

PERFORMANT FINANCIAL CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug...

Daniel Carlson -
0
Front Page

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society...

Daniel Carlson -
0
Front Page

INKmune: An Interview With INmune Bio’s Dr. Mark Lowdell

Daniel Carlson -
0
Front Page

QUEST RESOURCE HOLDING CORPORATION REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS

Daniel Carlson -
0
Anixa

Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine...

Daniel Carlson -
0
Front Page

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers...

Daniel Carlson -
0
Front Page

Summer Stocks

Daniel Carlson -
4
Front Page

TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business...

Daniel Carlson -
2
Front Page

LexaGene Demonstrates a Simple and Inexpensive Multiplex PCR Chemistry with Shorter...

Daniel Carlson -
0
Front Page

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184...

Daniel Carlson -
0
Performant

PERFORMANT FINANCIAL CORPORATION ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2021

Daniel Carlson -
0
Amryt

My Saturday Rant…

Daniel Carlson -
4
Front Page

Trading Blog, August 6, 2021

Daniel Carlson -
0
Amryt

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business...

Daniel Carlson -
0
Front Page

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe’s VenoValve

Daniel Carlson -
0
Amryt

Are We Having Fun Yet? Bull Ride Continues

Daniel Carlson -
6
Front Page

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating...

Daniel Carlson -
2
Front Page

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease...

Daniel Carlson -
5
Anixa

July About to Close With a Bang?

Daniel Carlson -
0
Front Page

ParkerVision Receives Second Favorable Markman Ruling in ParkerVision v. Intel

Daniel Carlson -
4
Front Page

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the...

Daniel Carlson -
0
Anixa

Back In The Torture Chamber

Daniel Carlson -
3
Front Page

INmune Bio, Inc. Announces $40 Million Registered Direct Offering

Daniel Carlson -
2
Front Page

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its...

Daniel Carlson -
4
Front Page

INmune Bio, Inc. Announces First Patient Treated with NK cell priming...

Daniel Carlson -
0
Front Page

Kentucky Bluegrass

Daniel Carlson -
3
Front Page

LexaGene Launches 2nd Generation Bacterial and Drug Resistance Test to Better...

Daniel Carlson -
0
Anixa

Let’s Get Ready To Rumble (2nd Half Preview)

Daniel Carlson -
2
Front Page

LexaGene Advances Towards FDA Emergency Use Authorization

Daniel Carlson -
0
Fortress Bio

Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s...

Daniel Carlson -
0
Amryt

Hoping for Fireworks

Daniel Carlson -
6
Front Page

Trading Blog, June 24, 2021

Daniel Carlson -
0
Front Page

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody...

Daniel Carlson -
1
Front Page

Put The Hammer Down…Backgammon Lessons

Daniel Carlson -
2
Front Page

LexaGene’s MiQLab Offers Rapid Plague Detection for Bioterrorism Threats

Daniel Carlson -
0
Front Page

Warrant Repo Is A Coup For INmune

Daniel Carlson -
1
Front Page

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor...

Daniel Carlson -
0
Front Page

QUEST RESOURCE HOLDING CORPORATION ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE ASSET-LIGHT WASTE...

Daniel Carlson -
0
Front Page

LexaGene Closes Sale to Alpine Veterinary Hospital

Daniel Carlson -
0
Amryt

Stock Picking Wins This Week

Daniel Carlson -
8
Fortress Bio

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and...

Daniel Carlson -
0
Fortress Bio

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted...

Daniel Carlson -
0
Front Page

LexaGene detects a slow-growing bacterium at least 36-times faster than conventional...

Daniel Carlson -
0
Front Page

Aducanumab Approval…Implications For INmune Bio

Daniel Carlson -
3
Front Page

LexaGene Sells a MiQLab System to Denver Animal Emergency

Daniel Carlson -
0
Front Page

TFF Pharmaceuticals Hosting Key Opinion Leader Perspectives on Thin Film Freezing...

Daniel Carlson -
2
Amryt

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee...

Daniel Carlson -
0
Amryt

Oregon Trails

Daniel Carlson -
2
Front Page

LexaGene Partners with Ethos Discovery to Develop New Companion Animal Diagnostic...

Daniel Carlson -
0
Amryt

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for...

Daniel Carlson -
0
Front Page

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug...

Daniel Carlson -
0
Amryt

Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for...

Daniel Carlson -
0
Front Page

LexaGene Takes Steps to List on the Nasdaq

Daniel Carlson -
0
Atomera

Resetting Expectations for TFF Pharma

Daniel Carlson -
3
Anixa

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian...

Daniel Carlson -
0
Front Page

ParkerVision Files Against LG for Patent Infringement

Daniel Carlson -
0
Front Page

Reversal of Fortune

Daniel Carlson -
2
Anixa

Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from...

Daniel Carlson -
0
Front Page

ParkerVision Secures Patent License and Settlement Agreement with Buffalo, Inc.

Daniel Carlson -
0
Front Page

Quest Resource Holding Corporation Reports First Quarter 2021 Financial Results

Daniel Carlson -
0
Fortress Bio

Mustang Bio and City of Hope Announce First Patient Dosed in...

Daniel Carlson -
0
Fortress Bio

Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate...

Daniel Carlson -
0
Anixa

Gas Lines and Inflation…Is This The 80’s?

Daniel Carlson -
6
Front Page

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business...

Daniel Carlson -
0
Amryt

Opportunity Knocks, Amryt Smartly Acquires Chiasma

Daniel Carlson -
2
Front Page

Summit Wireless Technologies Posts 181% Q1 2021 Revenue Increase and Guides...

Daniel Carlson -
0
Fortress Bio

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of...

Daniel Carlson -
0
Fortress Bio

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop...

Daniel Carlson -
0
Front Page

LexaGene Expands Its Sales Team

Daniel Carlson -
0
Amryt

The Beatings Will Continue Until Morale Improves…

Daniel Carlson -
4
Anixa

OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie

Daniel Carlson -
0